Imidazolyl-cyclic acetals

The present invention relates to the use of a TNF inhibitor, hence a therapeutically useful compound of formula I wherein R1 is optionally substituted heteroaryl; R2 is optionally substituted aryl or heteroaryl, preferably pyridyl or pyrimidinyl; R3 is hydrogen, optionally substituted alkyl, alkenyl, alkynyl, aryl, cycloalkenyl, cycloalkyl, heteroaryl or heterocycloalkyl; R4 -L3-R14, preferably L3, and R14 is optionally substituted amino or carbamoyl or ester; or L 3 methylene and R 14 is optionally substituted aryl, heteroaryl, hydroxy or amino; R5 is hydrogen, alkyl or hydroxyalkyl; or R4 and R5 taken together form a methylene group or an ace to which they are attached together form a ring; R6 is hydrogen or alkyl; and their m 0, 1 or 2 - and N-oxides or derivatives, their pharmaceutically acceptable salts and solvates, their pharmaceutical compositions and their use in atherosclerosis, and the production process. HE